ECOG-ACRIN E2408 trial: what clinicians have said so far
Bendamustine Hydrochloride and Rituximab With or Without Bortezomib Followed by Rituximab With or Without Lenalidomide in Treating Patients With High-Risk Stage II, Stage III, or Stage IV Follicular Lymphoma
- NCT01216683 ↗
- Completed
- ECOG-ACRIN Cancer Research Group
- Focused size, estimated: 1–150 verified statements once built
We haven't built an HCP commentary report on ECOG-ACRIN E2408 (bortezomib; lenalidomide in high-risk untreated follicular lymphoma) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on ECOG-ACRIN E2408 so far
Podcasts, YouTube videos and posts on X and Bluesky we have indexed that name the trial. LinkedIn posts are read for reports and the Enterprise MCP, not yet for this index. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Indexed so far | |
|---|---|
| 5 posts on X, typically up to 22 once built |
The trial
ClinicalTrials.gov- Official title
- A 3-Arm Randomized Phase II Trial of Bendamustine-Rituximab (BR) Followed by Rituximab vs Bortezomib-BR (BVR) Followed by Rituximab vs BR Followed by Lenalidomide/Rituximab in High Risk Follicular Lymphoma
- Phase
- Phase 2
- Status
- Completed
- Conditions
- Lymphoma
- Interventions
- rituximab; Bendamustin; bortezomib; lenalidomide
- Arms
- Arm A then Arm D (Induction with Bendamustine + Rituximab; Continuation with Rituximab) · Experimental
- Arm B then Arm E (Induction with Bendamustine + Rituximab + Bortezomib; Continuation with Rituximab) · Experimental
- Arm C then Arm F (Induction with Bendamustine+Rituximab; Continuation with Lenalidomide + Rituximab) · Experimental
- Enrollment
- 289
- Primary outcomes
- Complete Remission (CR) Rate
- 1-year Post-induction Disease-free Survival (DFS) Rate
- Sponsor
- ECOG-ACRIN Cancer Research Group with National Cancer Institute (NCI)
- Start
- Feb 9, 2011
- Primary completion
- Dec 2, 2019
- Results posted
- Yes
- Registry record
- NCT01216683 · updated Jun 29, 2023
Publications
linked from the registry- Evens AM, Hong F, Habermann TM, Advani RH, Gascoyne RD, Witzig TE, Quon A, Ranheim EA, Ansell SM, Cheema PS, Dy PA, O'Brien TE, Winter JN, Cescon TP, Chang JE, Kahl BS. A Three-Arm Randomized Phase II Study of Bendamustine/Rituximab with Bortezomib Induction or Lenalidomide Continuation in Untreated Follicular Lymphoma: ECOG-ACRIN E2408. Clin Cancer Res. 2020 Sep 1;26(17):4468-4477. doi: 10.1158/1078-0432.CCR-20-1345. Epub 2020 Jun 12. PubMed 32532790